Camille Bachot

What happens when over 1,500 scientists at Sanofi transition from legacy systems to Benchling? Real-time visibility into standardized data across teams is a critical starting point for their #ML models. See how more than 30 global teams at Sanofi are accelerating R&D with Benchling — from early discovery-omics such as precision oncology, to core therapeutic pipeline teams including novel modalities like mRNA, and all the way up the lifecycle to translational teams. https://lnkd.in/gamMp_yi #PoweredByAI #BuiltOnBenchling

18

1 commentaire

Leveraging RADAR, CRA’s orphan drug data repository, our #CRALifeSciences practices delves into pricing and market access trends of rare disease treatments in France. Several innovative pharmaceutical products have navigated the complex landscape of reimbursement over extended periods, exceeding five years for some due to prolonged time to clinical trial outcomes. Orphacol stands out as a remarkable achievement, being the sole product to achieve ASMR 1 status since 2013, granted within an impressive 160 days of EMA approval on its first submission. Additionally, Strensiq, Luxturna, Givlaari, and Kaftrio have attained ASMR 2, with early access through ATU preceding reimbursement, except for Strensiq. Furthermore, 32 products, averaging three per year, have secured ASMR 3, with five falling into mixed ASMR categories, including nine with reimbursement restrictions, reflecting the dynamic landscape of pharmaceutical reimbursement and access. For more information, click here: https://lnkd.in/gVEh-zps

42

🧬 DAY 1 | We’re thrilled to welcome you at #ISPOREurope in Barcelona! 🇪🇸 Come visit us at 𝐁𝐨𝐨𝐭𝐡 𝟕𝟎𝟑 to meet our team of experts: Stéphane DENIAU, and Marion VOUTE. 💡 Let’s dive into the latest breakthroughs and discuss how real-world data can drive deeper insights for better healthcare outcomes. We look forward to connecting with you! ISPOR—The Professional Society for Health Economics and Outcomes Research #ISPOREurope #ISPOR2024 #RealWorldData #HealthcareInsights

61

3 commentaires

Compounding in hospital pharmacy with #CSTD or #Luer-Lock? Come and visit us at The European Association of Hospital Pharmacists (EAHP) BOOST to see how The Compounder accommodates these methods! #EAHPBOOST #Pharmacy #HospitalPharmacy #HealthcareInnovation #AutomationInHealthcare #Florence2024 #HospitalTechnicians #PatientCare #PharmacyInnovation #HospitalPharmacists

7

Are you involved in implementing SDTM? Our new guide covers all the essentials you need to know about SDTM domains. Understanding SDTM domains is crucial for structuring clinical trial data effectively and ensuring compliance. Learn the five main classes of domains, and how each category organizes data - whether it's vital signs, lab results, or adverse events. Get your free guide here >> https://lnkd.in/eyWpuUsp #SDTMDomains #SDTMImplementation #SDTMGuidance #Certara

11

In just 2 years, Sanofi was able to increase ROI, Know Your Customer (KYC), simplify data management and governance, reduce risks, streamline operations, and lower TCO with Semarchy's Data Platform. While the solution rapidly met today’s needs, it is perfectly positioned to adapt to tomorrow’s changes just as fast. Check out the full interview with Sanofi 📽️ #mdm #dataplatform #datamanagement #data #masterdatamanagement #customerdata

58

3 commentaires

In just 2 years, Sanofi was able to increase ROI, Know Your Customer (KYC), simplify data management and governance, reduce risks, streamline operations, and lower TCO with Semarchy's Data Platform. While the solution rapidly met today’s needs, it is perfectly positioned to adapt to tomorrow’s changes just as fast. Check out the full interview with Sanofi 📽️ #mdm #dataplatform #datamanagement #data #masterdatamanagement #customerdata

22

In today’s fast-paced and constantly changing healthcare landscape, leveraging modern data infrastructure and technologies to stay ahead of the curve is crucial for trusted health solutions. Watch as Sanofi's Head of Customer Master Data Management demonstrates how the global company enabled a Customer 360 Solution in over 50 locations with Master Data Management and data engineering. #mdm #data #dataplatform #datamanagement #masterdata #customerdata https://hubs.ly/Q02WRnQ40

9

Hospital pharmacists play a critical role in patient care and need fast access to clinical information. At Hôpitaux de l’Est Lémanique in Switzerland, the pharmacy team relies on Micromedex for swift, evidence-based pharmacological insights that are hard to find elsewhere. Discover how #Micromedex empowers decision-making: https://lnkd.in/dAzW7biu #HospitalPharmacy #ClinicalDecisionSupport

50

🇫🇷 What do you know about clinical trials in France? Here is your chance to brush up on your previous knowledge or learn something brand new. Happy to announce yet another webinar in the series of sessions by #EUCROF on #ClinicalTrials in Europe.    We will explore the clinical research landscape in France and explain how this pioneering nation has become a leading global player.   We will cover a range of topics related to both drugs and medical devices:   👉Key figures and statistics in clinical research 👉Patient recruitment potential  👉Regulatory and ethical approval processes 👉Clinical research ecosystem: access to CROs, service providers, and vendors  👉Acceptability and evolution of decentralized trial methods 👉Cost considerations   Our presenters this time will be Laetitia Gidelle, Country Manager, PSI CRO AG France, Christophe CLEMENT, Business Development Director, ICTA , and Anne Peron, VP of BD, Biotrial. 📅 December 10 | 11:00 AM to 12:30 PM (CET) ⚡Follow the link to register https://lnkd.in/dMXdCK62   #cro #contractresearch #clinicalresearch #clinicaltrialsfrance

19

🇫🇷 What do you know about clinical trials in France? Here is your chance to brush up on your previous knowledge or learn something brand new. Happy to announce yet another webinar in the series of sessions by #EUCROF on #ClinicalTrials in Europe.    We will explore the clinical research landscape in France and explain how this pioneering nation has become a leading global player.   We will cover a range of topics related to both drugs and medical devices:   👉Key figures and statistics in clinical research 👉Patient recruitment potential  👉Regulatory and ethical approval processes 👉Clinical research ecosystem: access to CROs, service providers, and vendors  👉Acceptability and evolution of decentralized trial methods 👉Cost considerations   Our presenters this time will be Laetitia Gidelle, Country Manager, PSI CRO AG France, Christophe CLEMENT, Business Development Director, ICTA , and Anne Peron, VP of BD, Biotrial. 📅 December 10 | 11:00 AM to 12:30 PM (CET) ⚡Follow the link to register https://lnkd.in/dMXdCK62   #cro #contractresearch #clinicalresearch #clinicaltrialsfrance

6

This whitepaper uncovers critical aspects to driving intelligent automation – from finding your why to establishing a center of excellence (COE) – while presenting compelling data to help you transition from emerging or transforming to maturing. https://bit.ly/3YISGgT #pharmacovigilance #safetyPV

2

In case you missed it, Emmanuel Walckenaer, CEO of Yseop, discussed the importance of accuracy, security and intuitiveness in generative AI applications for medical writing in a recent interview with Euronews. The interview also highlighted Yseop's recent partnership with Amazon Web Services (AWS). Read the full article: https://bit.ly/4c8wTTD #AI #GenAI #GenerativeAI #Clinicaltrial #Pharma #Automation #Euronews #AWS

18

1 commentaire

Philosophy of ‘Black Swan Theory’ in pharmacovigilance Uppsala Monitoring Centre's report Adverse drug reactions (ADRs) can be classified into white, grey, and black swan events, offering flexibility in pharmacovigilance systems. Understanding “white swans” enables specialists to manage common ADRs effectively, improving patient safety. Characterizing “grey swans” based on pharmacological knowledge helps predict and prioritize potential signals. This approach allows pharmacovigilance systems to better handle unpredictable “black swan” events that significantly impact public health. Read more here: https://lnkd.in/e9m2tvMT

15

4 commentaires

France: The Pharma-Place-to-Be in 2024! 🌟 Exciting developments are happening in the pharmaceutical world, and France is at the forefront of it all. According to Fierce Pharma, major investments are pouring into R&D and manufacturing in the EU, with France taking a leading role. Sanofi is investing $1.1B in treatments for COPD, Asthma, MS, and T1D, along with over $100M to boost Dupixent and an additional $10M+ for TZIELD. AstraZeneca is committing nearly $400M to its initiatives. Pfizer plans to spend over $500M on R&D in the next five years. These are just a few examples, with other significant investments coming from AbbVie, Novartis, Kenvue, and Chiesi Group. What's particularly intriguing is the dynamic shift we're witnessing: while the EU, particularly France, is becoming a hub for R&D and manufacturing, US companies are focusing on direct-to-patient initiatives. This includes direct contracts with pharmacies, diagnostics, and telehealth providers. 🔄 Produce and Innovate in Europe, Sell in the US 🔄 The future of pharma looks promising with this transatlantic synergy! For more insights, check out the full article from Fierce Pharma: https://lnkd.in/dQ9rB6ks

7

🚀Do it way faster! 🚀 Tired of the tedious grind of manual literature screening? Watch how our DrugCard platform transforms hours of work into minutes, boosting efficiency and accuracy for PV specialists. Ready to supercharge your pharmacovigilance processes? Click play and see the future in action! 🔍 💼 #pharmacovigilance #drugsafety #literaturemonitoring #PV

20

2 commentaires